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Abstract
Introduction: Haemoglobin A1c (HbA1c) is a key analyte for the monitoring of glycemic balance in diabetic patients and is used for diabetes diagno-
sis in many countries. The potential interference of carbamylated haemoglobin (cHb) and labile glycated haemoglobin (LA1c) on HbA1c assays must 
remain a matter of vigilance. Such a situation has occurred in our laboratory with a kit replacement on the Bio-Rad Variant™ II testing system, a 
cation-exchange high performance liquid chromatography (HPLC) system. With this method, LA1c and cHb coeluted in a same peak which may have 
different consequences on HbA1c values.
Materials and methods: The influence of increasing LA1c and cHb values on HbA1c results was studied with in vitro glycation and carbamylation 
of samples. Samples from patients with high and normal blood urea concentrations were assayed by HPLC and immunological assay.
Results: We observed that the degree of interference greatly varied depending on the nature of the interfering Hb fractions found under the so-
called “LA1c peak”. Thus, we have decided to apply a decision tree using “LA1c” thresholds depending on: (i) the retention time, (ii) the shape of the 
peak, (iii) other analytes, like urea. If the peak recognized as “LA1c” is mainly formed by LA1c, we consider that there is no interference until 4%. If the 
peak is mainly formed by cHb, we consider an interference threshold equal to 2%. 
Conclusions: This situation reminds that cHb and LA1c remain critical issues in chromatography-based HbA1c assays and that adapted criteria must 
be set up for result interpretation.
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Since its discovery as unusual haemoglobin frac-
tion in patients with diabetes mellitus, HbA1c, the 
major component of glycated haemoglobin, has 
proved to be a useful analyte for the monitoring of 
glycemic balance in diabetic patients, and for dia-
betes diagnosis in many countries (1–3). HbA1c is 
also an important predictive marker of long term 
complications of diabetes (4,5). HbA1c assays can 
be performed using different analytical principles 
including separative methods such as high perfor-
mance liquid chromatography (HPLC) and capil-
lary electrophoresis, but also immunological and 
enzymatic methods. 
The quality of assay methods for HbA1c determina-
tion has greatly improved over the last decades, 
and most of analytical interferences have been 
controlled (1,6). This is the case of carbamylated 
haemoglobin (cHb), which results from the bind-
ing of urea-derived isocyanic acid and is increased 
in patients with chronic kidney disease. However, 
the potential interference of cHb on HbA1c assays 
must remain of matter of vigilance (7,8). Further-
more, interference may be caused by labile glycat-
ed haemoglobin (LA1c), a labile and reversible frac-
tion (Schiff base) formed at early stages of glyca-
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tion reaction, which directly depends on blood 
glucose concentration. Such a situation is reported 
here. 
We have recently changed the kit for HbA1c deter-
mination in our laboratory, by replacing the NU 
Kit™ by the Dual Kit Program™ on the Bio-Rad Vari-
ant™ II testing system, based on cation-exchange 
HPLC. The analyser used for determination of 
HbA1c is the same, but the chromatography pro-
gram (column, buffer gradient) and the peak inte-
gration software (column, buffer gradient) are dif-
ferent. The main advantage of the method with 
the new kit is the possibility to use the same meth-
od for HbA1c, haemoglobin A2, and haemoglobin F 
measurements.
Most frequent interferences encountered with 
such HPLC-based methods have been evaluated 
(9). Whereas previous evaluations of this system 
did not report any interference studies (10), the in-
struction notes of the manufacturer mention a po-
tential interference of cHb and LA1c over 3%. Using 
the Dual kit program™, LA1c and cHb coeluted in a 
same peak called LA1c, contrary to the former pro-
gram NU Kit™ which allowed the separation in two 
peaks. As these two minor Hb fractions coelute in 
a single peak before HbA1c peak, the consequenc-
es on HbA1c value may differ according to the in-
creased fractions (cHb or LA1c). Indeed, besides re-
porting the differences of chromatographic sepa-
ration of cHb and LA1c between the two kits, the 
aim of this study was to evidence that the influ-
ence of cHb or LA1c on HbA1c measurements re-
mains a critical issue and to propose a decision 
tree for managing these interferences in routine 
practice with this method.
Materials and methods
Subjects
This study was performed from September to Oc-
tober 2016 in the Laboratory of Pediatric Biology 
and Research at the University Hospital of Reims.
Blood samples used for this study were received in 
the routine workload of the laboratory for HbA1c 
assay as part of the follow-up of 19 patients. The 
interference noticed with the new kit was evi-
denced during regularly ordered HbA1c assays. No 
other biological investigation than HbA1c assay 
was performed, and additional experiments exclu-
sively aimed at providing an interpretable HbA1c 
result in patients. 
Among these samples, those from patients with 
physiological (< 7.15 mmol/L) or increased blood 
urea (> 7.15 mmol/L) were assayed by two meth-
ods (HPLC and immunological assay). 
Blood samples
Blood samples sent to the laboratory for HbA1c as-
says using Variant II™ analyser were collected in 5 
mL ethylenediamine tetra-acetic acid dipotassium 
salt (K2EDTA)-containing tubes (ref. 367962, Bec-
ton Dickinson, Franklin Lakes, New Jersey, USA) 
and stored at + 4°C before analysis. The minimum 
required volume, for the primary tube, was 1 mL. 
For DCA Vantage analyser, 1µL of capillary blood, 
obtained by finger skin puncture or venous punc-
tion (acceptable anticoagulants being K2EDTA, 
heparin, fluoride/oxalate and citrate) was required. 
Capillary holders, which contain glass capillary, are 
provided by Siemens in DCA™ Systems Hemo-
globin A1c Reagent Kit. 
For urea measurement, blood samples were col-
lected on lithium heparin-containing tubes (ref. 
367884, Becton Dickinson, Franklin Lakes, New Jer-
sey, USA). The minimum required volume was 1 
mL for primary tubes. 
Methods
Blood urea was assayed on Cobas 8000 modular 
analyser series on c701 and c502 modules (Roche 
Diagnostics, Mannheim, Germany). Determination 
of blood urea was based on kinetic test using ure-
ase and glutamate dehydrogenase. 
Variant II Hemoglobin Testing System™ (Bio-Rad, 
Marnes-la-Coquette, France) is a completely auto-
mated system for HbA1c measurement based on 
cation-exchange HPLC. Samples are automatically 
mixed, diluted on the station and injected into the 
column. Haemoglobins are separated based on 
their ionic interactions with the stationary phase. 
The mobile phase is composed of phosphate buff-
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er; the chromatographic station delivers a gradi-
ent of increasing ionic strength to the cartridge. 
The separated haemoglobins pass through the 
flow cell of the filter photometer, and changes in 
the absorbance are measured at 415 nm, and at 
690 nm for background correction. 
Intra-assay coefficients of variation (CVs), calculat-
ed from patient samples, were 0.4%, 0.7% and 
0.4% for HbA1c values (expressed in percentages) 
of 5.4%, 7.3% and 12.8%, respectively. Between-as-
say CVs, calculated from quality control results, 
Bio-Rad Lyphocheck Diabetes Controls (Bio-Rad 
Laboratories Inc, Hercules, CA, USA), were 1.1% 
and 1.3% for HbA1c values of 5.7% and 9.4%, re-
spectively. Measurement uncertainties represent-
ed 0.27% and 0.38% for HbA1c values of 5.6% and 
9.4%, respectively. Bio-Rad Lyphocheck Diabetes 
Controls were used as quality control (QC) materi-
als and assayed at the beginning and at the end of 
each assay series. Between-assay CVs were 1.0% 
and 1.2% for expected values at 5.2% and 10.1% of 
HbA1c respectively.
DCA Vantage (Siemens Healthcare, St Denis, 
France) system relies on an immunological assay. 
The concentrations of HbA1c and total haemoglo-
bin are both measured in parallel and the ratio re-
ported as percent. For total haemoglobin meas-
urement, haemoglobin is oxidized in methaemo-
globin, then methaemoglobin complexes with 
thiocyanate to form thiocyan-methaemoglobin, 
the absorbance of coloured species being meas-
ured at 531 nm. The measurement of HbA1c is 
based on a latex agglutination inhibition method 
using monoclonal antibodies. An agglutinator, 
containing immunoreactive portion of HbA1c, 
causes the agglutination of latex particles coated 
with HbA1c monoclonal antibody. The agglutina-
tion reaction increases scattering of light meas-
ured as an increase of absorbance at 531 nm. HbA1c 
in patient blood sample inhibits the interaction 
between the agglutinator and latex particles and 
decreases scattering of light, measured as a de-
crease in absorbance at 531 nm. 
Intra-assay CVs, calculated from patient samples, 
were 1.5% and 2.7% for HbA1c values (expressed in 
percentages) of 5.2% and 7.7%, respectively. Be-
tween-assay CVs, calculated from quality control 
results (Bio-Rad Lyphocheck Diabetes Controls) 
were 1.8% and 1.7% for HbA1c values of 5.6% and 
10.2%, respectively. Measurement uncertainties 
represented 0.61% and 0.67% for HbA1c values of 
5.6% and 10.2%, respectively. Bio-Rad Lyphocheck 
Diabetes Controls were used as QC materials and 
assayed at the beginning and at the end of each 
assay series. Between-assay CVs were 1.8% and 
2.3% for expected values at 5.6% and 9.9% of 
HbA1c, respectively.
In the Dual kit program™, LA1c and cHb coeluted in 
a same peak called LA1c, contrary to the former 
program NU Kit™ which allowed the separation in 
two peaks. This peak, which elutes just before 
HbA1c peak, may represent a potential interference 
on HbA1c quantification. 
Procedures for in vitro carbamylation and glycation
Whole blood samples were selected according the 
following criteria: haematocrit value in reference 
ranges, low LA1c value (< 1.5%), and two HbA1c lev-
els (within reference range and over 7%).
Two mL of whole blood were centrifuged (4 °C, 8 
minutes, 3000g), plasma removed, and three 
washes (4 °C, 8 minutes, 3000 x g) of red blood 
cells (RBC) performed with NaCl 0.15 M (saline). 
200 µL of KCNO (Sigma-Aldrich, St Louis, Missouri, 
USA), prepared at different concentrations: 
0.125 mM, 0.250 mM, 0.375 mM, 0.500 mM, 0.750 
mM, were added and incubated for 3 hours at 37 
°C. A control series was performed by incubating 
200 µL KCl instead of KCNO. After centrifugation 
(room temperature (RT), 30 seconds, 20,000 x g), 
supernatant was removed and 2 washes were per-
formed (RT, 30 seconds, 20,000 x g) with saline. 
200 µL of saline were added, and HbA1c assayed on 
Variant II™ system. 
Procedure for in vitro glycation
Two mL of whole blood were centrifuged (4 °C, 8 
minutes, 3000 x g), plasma removed, and three 
washes of RBC performed with saline. 200 µL of 
0.250 mM glucose (alpha-D-glucose anhydrous 
96%; Sigma-Aldrich, St Louis, Missouri, USA) solu-
tion in saline were added to RBC pellet and incu-
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bated for 0, 15, 17, 22, 27, 30, 45 minutes at 37 °C. 
After centrifugation (RT, 30 seconds, 20,000 x g), 
supernatant was removed and replaced by 200 µL 
of 5 mM glucose, and HbA1c assayed on Variant II™ 
system. 
Statistical analysis
In vitro glycation or carbamylation experiments 
were analysed in triplicate. Results were expressed 
as means. 
Relative and absolute biases were obtained with 
following formulas: 
Relative bias = 





where x = HbA1c measured with Variant II ™ ana-
lyser and y = HbA1c measured with DCA Vantage 
analyser.
Uncertainty measurement (U) was calculated us-
ing the following formulas: 
U = 2 × u(C)
u(IQC) = 
CV × m 
100











Σi (Ei – E )2
n – 1
=
Σi (xlab – xref )i
n
E =
(xlab – xref )Ei =
where IQC represents internal quality control, EQE 
external quality control, CV coefficient of variation, 
m represents the mean; xlab laboratory result; xref 
reference value.
The measurement uncertainty of the Variant 
II™system, calculated with the above formulas and 
equal to 0.3%, was used as a threshold to deter-
mine a significant difference between HbA1c re-
sults.
Results
First, we studied the influence of increasing LA1c 
values on HbA1c results, and showed that the in-
crease of LA1c peak led to a decrease of HbA1c val-
ues (Table 1), the threshold of 0.3% being used as 
acceptance criterion to determine a significant dif-
ference between HbA1c results. Thus, a significant 
interference was noticed when LA1c exceeded 4%. 
Second, we studied the influence of cHb interfer-
ence and found a significant interfering effect 
when cHb exceeded 2% (Table 2). 
Thus, both LA1c and cHb interfered with HbA1c de-
termination, but it was noteworthy that the influ-
ence of the peak recognized as LA1c on chromato-
gram depended on the nature of the interference. 
When the interference was caused by cHb, HbA1c 
decrease was more prominent than when caused 
by LA1c. For example, for an initial level of HbA1c 
equal to 5.2% (33 mmol/mol) with a LA1c peak at 
1.2%, the increase of LA1c peak to 3.4 % due to gly-
cation (LA1c increase) led to a decrease of HbA1c val-
ue to 4.9% (30 mmol/mol), whereas it was 4.4% (25 
mmol/mol) when the interference was due to car-
bamylation (cHb). Similar results were found using a 
sample with initial HbA1c value of 8.1% (65 mmol/
mol): a decrease of HbA1c to a value at 7.7% (61 
mmol/mol) was observed for a cHb value of 2.2% 
whereas it was observed only at 4.6% of LA1c (Tables 
1 and 2). The impact of cHb and LA1c on the HbA1c 
measurements (Tables 1 and 2) was also highlight-
ed using a graphical presentation (Figure 1).
Interestingly, we observed that chromatograms 
differed regarding retention time (higher for cHb 
than for LA1c) and peak shape depending on the 
origin of the interference (LA1c or cHb), even 
though the peak was only recognized as LA1c by 
the software (Figure 2). 
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Incubation time (min) with 0 .25 mol/L glucose 0 15 17 22 27 30 45
HbA1c†, mmol/mol 33 31 30 30 28 27 25
HbA1c†, % 5.2 5.0 4.9 4.9 4.7* 4.6* 4.4*
Peak recognized as «LA1c»†, % 1.2 3.1 3.4 4.0 4.5 4.8 6.3
HbA1c†, mmol/mol 65 64 64 62 61 60 56
HbA1c†, % 8.1 8.0 8.0 7.8 7.7* 7.6* 7.3*
Peak recognized as «LA1c»†, % 1.3 3.1 3.4 4.0 4.6 4.8 6.2
*Differences higher than 0.3% compared to initial value of HbA1c. †mean of triplicate measurements.
Table 1. Interference of labile glycated hemoglobin (LA1c) on HbA1c measurements by Variant II equipped with Dual kit program™ 
3h-incubation with KCNO (mmol/L) 0 .000 0 .125 0 .250 0 .375 0 .500 0 .750
HbA1c†, mmol/mol 33 32 31 30 28 25
HbA1c†, % 5.2 5.1 5.0 4.9 4.7* 4.4*
Peak recognized as «LA1c»†, % 1.2 1.4 1.7 2.1 2.5 3.4
HbA1c†, mmol/mol 65 64 61 59 55 50
HbA1c†, % 8.1 8.0 7.7* 7.5* 7.2* 6.7*
Peak recognized as «LA1c»†, % 1.3 1.6 2.2 2.8 3.5 4.8
*Differences higher than 0.3% compared to initial value of HbA1c. †Mean of triplicate measurements.
Table 2. Interference of carbamylated hemoglobin (cHb) on HbA1c measurements by Variant II equipped with Dual kit program™
To go further into the investigation of the impact 
of cHb on HbA1c measurements, we performed a 
comparison between HbA1c values obtained with 
the Dual Kit Program™ (Bio-Rad) device and with 
the immunoassay-based DCA Vantage (Siemens 
Healthcare) which is not influenced by cHb (11). Be-
cause uraemia is the main cause of increased car-
bamylation (12), and consequently of cHb forma-
tion, samples from 7 patients with increased blood 
urea (> 7.15 mmol/L) were assayed by both meth-
ods. Negative absolute and relative biases were 
evidenced in all samples with increased blood 
urea. Mean relative and absolute biases calculated 
were - 8.2% and - 5 mmol/L (- 0.5%), respectively 
(Table 3). By contrast, a similar comparison per-
formed in samples from patients without hyperu-
raemia (urea < 7.15 mmol/L) showed mean relative 
and absolute biases equal to + 0.9% and +1.1 
mmol/mol (+ 0.1%) respectively (Table 4).
Discussion
Because HbA1c is widely used for the diagnosis of 
diabetes and the monitoring of diabetic patients, 
its quantification must be performed using robust 
and high quality methods (2). HPLC is commonly 
used for assaying HbA1c, and the potential interfer-
ences, like those generated by LA1c and cHb, have 
generally been well described. However, these ad-
ditional Hb fractions may still cause unexpected 
interferences (7,8,13). A previous study investigat-
ing the influence of cHb to HbA1c measurements 
by Bio-Rad Variant II™ analyser equipped with NU 
Kit™ did not evidence such an impact of cHb but 
recommended an interpretation with caution 
when cHb was increased (14).
Using the Dual kit program™, LA1c and cHb coelut-
ed in a same peak called LA1c, contrary to the for-
mer program NU Kit™ which allowed the separa-
tion in two peaks. This peak which elutes just be-
fore HbA1c peak could represent a potential inter-
ference on HbA1c quantification. 
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Figure 1. Interference of LA1c (A) and cHb (B) on HbA1c measurement by Variant II equipped with Dual Kit Program™. 
For each interference, two samples with different levels of HbA1c (5.2% and 8.1%) have been tested. The dashed lines represent the 
values above which the differences have been considered significant (initial HbA1c values ± 0.3%, which corresponds to the measure-
ment uncertainty of the method).
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Figure 2. Chromatograms obtained in case of an increase of the “LA1c peak” due to A: LA1c (elution time: 0.63 min) or B: cHb (elution 
time: 0.71 min).
Biochemia Medica 2017;27(2): 378–86  https://doi.org/10.11613/BM.2017.039 
384












Patient 1 31 (5.0) 40 (5.8) - 13.7 - 9 (- 0.8) 27.8
Patient 2 53 (7.0) 58 (7.5) - 6.6 - 5 (- 0.5) 25.0
Patient 3 38 (5.6) 42 (6.0) - 6.6 - 4 (- 0.4) 15.3
Patient 4 55 (7.2) 58 (7.5) - 4.0 - 3 (- 0.3) 29.0
Patient 5 27 (4.6) 33 (5.2) - 11.5 - 5 (- 0.6) 9.0
Patient 6 30 (4.9) 34 (5.3) - 7.6 - 4 (- 0.4) 30.9
Patient 7 44 (6.2) 48 (6.7) - 7.5 - 4 (- 0.5) 24.0
Mean biases - 8.2 - 5 (- 0.5)









Patient 1 37 (5.5) 37 (5.5) 0.0 0 (0.0) 4.2
Patient 2 88 (10.2) 79 (9.4) 8.5 9 (0.8) 7.0
Patient 3 50 (6.7) 46 (6.4) 4.7 4 (0.3) 7.0
Patient 4 34 (5.3) 34 (5.3) 0.0 0 (0.0) 7.0
Patient 5 58 (7.5) 57 (7.4) 1.4 1 (0.1) 7.0
Patient 6 53 (7.0) 53 (7.0) 0.0 0 (0.0) 5.4
Patient 7 37 (5.5) 39 (5.7) - 3.5 - 2 (- 0.2) 5.7
Patient 8 41 (5.9) 41 (5.9) 0.0 0 (0.0) 7.1
Patient 9 40 (5.8) 42 (6.0) - 3.3 - 2 (- 0.2) 7.1
Patient 10 62 (7.8) 61 (7.7) 1.3 1 (0.1) 7.0
Mean biases + 0.9 + 1.1 (+ 0.1)
*Determined using Variant II. †Determined using DCA Vantage.
Table 3. Comparison of HbA1c results obtained using Variant II Dual kit program™ and DCA Vantagein patients with hyperuraemia
Table 4. Comparison of HbA1c results obtained using Variant II Dual kit program™ and DCA Vantage in non-uraemic patients
In this study, we have evidenced that although mi-
grating under the same peak; both LA1c and cHb 
interfered differentially with HbA1c measurements. 
Indeed, the degree of interference greatly varied 
depending on the nature of the interfering Hb 
fractions found under the so-called “LA1c peak”. In 
the case of the present method, manufacturer rec-
ommendations indicated the absence of interfer-
ence of the peak recognized as LA1c fewer than 
3%. Our study evidenced that a significant inter-
ference was noticed when LA1c exceeded 4% and 
found a significant interfering effect when cHb ex-
ceeded 2%. This interference caused by cHb could 
lead to underestimate the value of HbA1c and have 
an impact on clinical classifications based on HbA1c 
thresholds, or even on patient management (15).
Thus, we have decided to apply different thresh-
olds depending on the nature of the interference, 
according to decision tree shown in Figure 3. For 
differentiating the origin of the interference, we 
consider (i) the retention time, (ii) the shape of the 
peak, and (iii) other biological results, especially 
uraemia. If the peak recognized as “LA1c” is mainly 
formed by LA1c, we consider that there is no inter-
ference until 4% of LA1c. When LA1c is increased 
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over 4%, this fraction is eliminated by incubation 
of red blood cells for 30 minutes at 37 °C, accord-
ing to a previously described procedure (16). If the 
peak is mainly formed by cHb, we consider a lower 
interference threshold of 2%. When cHb values are 
higher than 2%, as cHb cannot be eliminated, we 
do not release values obtained by the HPLC meth-
od and perform HbA1c assay using an immunologi-
cal method, such as on DCA Vantage System, not 
influenced by cHb.
Conclusion
This article reminds that cHb remains a critical is-
sue in chromatography-based HbA1c assays. The 
experimental verifications performed upon imple-
mentation of the method in our laboratory led us 
to change our practice, considering the coelution 
in a single peak of LA1c and cHb. For that reason, 
the use of different thresholds (2% or 4% of LA1c 
peak) has been established in our daily practice.
Potential conflict of interest
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Figure 3. Decision tree in case of “LA1c peak” higher than 2%
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